Cartherics Raises Over $15 Million In Oversubscribed Private Financing Round To Advance Cell Therapy Programs

This funding will support the initiation of the clinical trial for CTH-401, the Company’s lead cell therapy product, aimed at treating ovarian cancer, as well as broadening its pipeline to include other disease indications.